Davide Golinelli

Dr. Davide Golinelli


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
DGDavide Golinelli
Davide Golinelli
EBErik Boetto
Erik Boetto
GCGherardo Carullo
Gherardo Carullo
ANAndrea Giovanni Nuzzolese
Andrea Giovanni Nuzzolese
MLMaria Paola Landini
Maria Paola Landini
MFMaria Pia Fantini
Maria Pia Fantini
Background: The COVID-19 pandemic is favoring digital transitions in many industries and in society as a whole. Health care organizations have responded to the first phase of the pandemic by rapidly adopting digital solutions and advanced technology tools. Objective: The aim of this review is to describe the digital solutions that have been reported in the early scientific literature to mitigate the impact of COVID-19 on individuals and health systems. Methods: We conducted a systematic review of early COVID-19–related literature (from January 1 to April 30, 2020) by searching MEDLINE and medRxiv with appropriate terms to find relevant literature on the use of digital technologies in response to the pandemic. We extracted study characteristics such as the paper title, journal, and publication date, and we categorized the retrieved papers by the type of technology and patient needs addressed. We built a scoring rubric by cross-classifying the patient needs with the type of technology. We also extracted information and classified each technology reported by the selected articles according to health care system target, grade of innovation, and scalability to other geographical areas. Results: The search identified 269 articles, of which 124 full-text articles were assessed and included in the review after screening. Most of the selected articles addressed the use of digital technologies for diagnosis, surveillance, and prevention. We report that most of these digital solutions and innovative technologies have been proposed for the diagnosis of COVID-19. In particular, within the reviewed articles, we identified numerous suggestions on the use of artificial intelligence (AI)–powered tools for the diagnosis and screening of COVID-19. Digital technologies are also useful for prevention and surveillance measures, such as contact-tracing apps and monitoring of internet searches and social media usage. Fewer scientific contributions address the use of digital technologies for lifestyle empowerment or patient engagement. Conclusions: In the field of diagnosis, digital solutions that integrate with traditional methods, such as AI-based diagnostic algorithms based both on imaging and clinical data, appear to be promising. For surveillance, digital apps have already proven their effectiveness; however, problems related to privacy and usability remain. For other patient needs, several solutions have been proposed, such as telemedicine or telehealth tools. These tools have long been available, but this historical moment may actually be favoring their definitive large-scale adoption. It is worth taking advantage of the impetus provided by the crisis; it is also important to keep track of the digital solutions currently being proposed to implement best practices and models of care in future and to adopt at least some of the solutions proposed in the scientific literature, especially in national health systems, which have proved to be particularly resistant to the digital transition in recent years.

1 July 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
FSFrancesco Sanmarchi
Francesco Sanmarchi
DGDavide Golinelli
Davide Golinelli
JLJacopo Lenzi
Jacopo Lenzi
FEFrancesco Esposito
Francesco Esposito
ACAngelo Capodici
Angelo Capodici
DGDino Gibertoni
Dino Gibertoni
During the SARS-CoV-2 pandemic, a surge in overall deaths has been recorded in many countries, most of them likely attributable to COVID-19. However, COVID-19 confirmed mortality (CCM) is considered an unreliable indicator of COVID-19 deaths because of national health care systems’ different capacities to correctly identify people who actually died of the disease.1,2 Excess mortality (EM) is a more comprehensive and robust indicator because it relies on all-cause mortality instead of specific causes of death.3 We analyzed the gap between the EM and CCM in 67 countries to determine the extent to which official data on COVID-19 deaths might be considered reliable.

18 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DGDavide Golinelli
Davide Golinelli
EBErik Boetto
Erik Boetto
EMElisa Maietti
Elisa Maietti
MFMaria Pia Fantini
Maria Pia Fantini
At present, existing evidence about the association between SARS-CoV-2 infection and ABO blood group polymorphism is preliminary and controversial. In this meta-analysis we investigate this association and determine SARS-CoV-2 positive individuals’ odds of having a specific blood group compared to controls. We performed a systematic search on MEDLINE and LitCovid databases for studies published through July 15, 2020. Seven studies met inclusion criteria for meta-analysis, including a total of 13 subgroups of populations (7503 SARS-CoV-2 positive cases and 2962160 controls). We analysed the odds of having each blood group among SARS-CoV-2 positive patients compared with controls. Random-effects models were used to obtain the overall pooled odds ratio (OR). Subgroup and sensitivity analyses were performed in order to explore the source of heterogeneity and results consistency. The results of our meta-analysis indicate that SARS-CoV-2 positive individuals are more likely to have blood group A (pooled OR 1.23, 95%CI: 1.09–1.40) and less likely to have blood group O (pooled OR = 0.77, 95%CI: 0.67–0.88). Further studies are needed to investigate the mechanisms at the basis of this association, which may affect the kinetics of the pandemic according to the blood group distribution within the population.

4 January 2023 in Applied Sciences
Verified
Journal Article
Open access
PDF file
MFMatteo Fiore
Matteo Fiore
Angelo CapodiciAngelo Capodici
Angelo Capodici
PRPaola Rucci
Paola Rucci
ABAlessandro Bianconi
Alessandro Bianconi
GLGiulia Longo
Giulia Longo
DGDavide Golinelli
Davide Golinelli
A supply chain (SC) is a network of interests, information, and materials involved in processes that produce value for customers. The implementation of blockchain technology in SC management in healthcare has had results. This review aims to summarize how blockchain technology has been used to address SC challenges in healthcare, specifically for drugs, medical devices (DMDs), and blood, organs, and tissues (BOTs). A systematic review was conducted by following the PRISMA guidelines and searching the PubMed and Proquest databases. English-language studies were included, while non-primary studies, as well as surveys, were excluded. After full-text assessment, 28 articles met the criteria for inclusion. Of these, 15 (54%) were classified as simulation studies, 12 (43%) were classified as theoretical, and only one was classified as a real case study. Most of the articles (n = 23, 82%) included the adoption of smart contracts. The findings of this systematic review indicated a significant but immature interest in the topic, with diverse ideas and methodologies, but without effective real-life applications.

22 September 2025 in Health Policy
Verified
Journal Article
Open access
DGDavide Golinelli
Davide Golinelli
FSFrancesco Sanmarchi
Francesco Sanmarchi
GGGiovanni Guarducci
Giovanni Guarducci
JPJacopo Palombarini
Jacopo Palombarini
PBPaolo Benetti
Paolo Benetti
JLJacopo Lenzi
Jacopo Lenzi
Understanding gender-based disparities in healthcare utilization is crucial for informing equitable health policy. However, cross-national evidence across multiple service domains in Europe remains limited. To examine gender differences in healthcare utilization across 27 European countries and explore variability across service types. We analyzed data from 257,388 adults in the third wave of the European Health Interview Survey (2019-2020). Twelve healthcare utilization indicators were evaluated, including hospital admissions, outpatient care, mental health services, and medication use. Gender disparities were estimated using regression models with inverse probability weighting based on random forest propensity scores. Women had significantly higher odds of using nearly all outpatient and preventive services, including general practitioners, specialists, dental care, physiotherapy, psychotherapy, and home care. They also reported higher use of both prescribed and non-prescribed medications. No significant gender differences were observed in hospitalization rates. Sensitivity analyses adjusting for health needs confirmed these findings. Considerable heterogeneity emerged across countries and service domains: Latvia, Lithuania, and Poland showed the largest disparities (e.g., ORs 1.52-1.75 for recent specialist visits), while Denmark, the Netherlands, and Ireland displayed relatively small overall gaps but large differences for specific services, such as psychotherapy and home care. Women consistently utilize more non-acute healthcare services than men, while comparable hospitalization rates suggest differences in disease severity or care-seeking behaviors. The magnitude of these disparities varies considerably across European countries, highlighting the need for context-sensitive policies to address gender inequities in healthcare utilization.

15 February 2022 in Health Policy and Technology
Verified
Journal Article
Closed access
CRChiara Reno
Chiara Reno
FSFrancesco Sanmarchi
Francesco Sanmarchi
MSMichael A. Stoto
Michael A. Stoto
MFMaria Pia Fantini
Maria Pia Fantini
JLJacopo Lenzi
Jacopo Lenzi
DGDavide Golinelli
Davide Golinelli